LGD 2941
Alternative Names: LGD-2226; LGD-2941; LGD122941Latest Information Update: 24 Jan 2013
At a glance
- Originator Ligand Pharmaceuticals
- Class Aminoquinolines; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cachexia; Female sexual dysfunction; Hypogonadism; Male sexual dysfunction; Menopausal syndrome; Osteoporosis
Most Recent Events
- 18 Jun 2008 Pharmacokinetics and adverse events data from a Phase-I trial in healthy volunteers presented at the 90th Annual Meeting of the Endocrine Society (ENDO-2008)
- 11 Oct 2007 Preclinical data added to the Musculoskeletal Disorders and Women's Health pharmacodynamics sections
- 11 Sep 2007 Phase I development is ongoing in Osteoporosis in USA (PO)